Oncovita SAS

Paris, France, October 9th, 2024 - Oncovita, a biotechnology company specializing in the development of therapeutic cancer vaccines and prophylactic vaccines, today announced the appointment of Dr. Stéphane Altaba as its new Chief Executive Officer. Stéphane Altaba is an experienced leader with over 25 years of experience in pharmaceutical firms and biotechnology entrepreneurship. He began his career in R&D, particularly in the development of biotechnological processes at Sanofi, before taking on corporate business development roles at Sanofi and Nordic Pharma. Mr. Altaba subsequently held various senior management positions, including General Manager of Nordic Pharma Spa in Italy, as well as COO and CEO roles in biotechnology companies such as Genomic Vision, LX Repair and RivelaDX. With a background in agricultural engineering, Mr. Altaba holds a Ph.D. in bioproduction and completed a post-doctoral fellowship in Japan. He is graduated from ESCP Business School. "We are delighted to announce the appointment of Stéphane Altaba as our new CEO. His appointment marks a new phase in Oncovita's development, and Stéphane brings a proven track record in leading R&D projects, as well as experience in licensing and collaboration agreements, which are crucial areas for our current stage of development. We congratulate Stéphane and wish him great success in his new role," said Dr. Jean-François Le Bigot, Executive Chairman of Oncovita. "I am thrilled to have the opportunity to join Oncovita as CEO. What attracted me to this project is, of course, the remarkable scientific quality of the team and the already validated MeasovirR technology platform, combined with a strategic vision and market positioning that are very promising. I am also highly motivated by the potential medical advancements that Oncovita aims to achieve, particularly in oncology, where there remains a significant unmet medical need," said Stéphane Altaba, CEO of Oncovita. "Leading Oncovita at our current stage of development requires a diverse set of skills, including an understanding of complex scientific projects and extensive experience in agreements and licensing. We are delighted to welcome Stéphane, who brings solid expertise in all these areas," concluded Professor Frédéric Tangy, co-founder and CSO of Oncovita. Press contact: Florence Portejoie, FP2COM, fportejoie@fp2com.fr, 06 07 76 82 83 A propos d’Oncovita : Oncovita is a biotechnology company dedicated to the design and development of novel therapeutic vaccines in oncology and prophylactic vaccines for infectious diseases. Its vaccine candidates are developed using its proprietary MeasovirR technology platform, which enables the modification of the measles vaccine virus genome, the most widely used and safest vaccine in the world. This "plug-and-play" platform has the capability to generate candidates with high apoptotic immunogenic activity. Oncovita’s mission is to advance its candidates from the preclinical stage through to clinical proof of concept. At the end of 2023, the company was selected as a laureate of the “Innovations in Biotherapies and Bioproduction” call for projects under the Innovation Santé France 2030 plan and received €4.5 million in funding as part of the France 2030 investment plan, managed by Bpifrance. In parallel, Oncovita completed a €3.5 million fundraising round with private investors. These two sources of funding, totaling €8 million, support the development of its MVdeltaC immunotherapeutic vaccine in oncology. https://www.oncovita.fr Attachment Oncovita_PR_Appointment_Stephane_Altaba_VDEF

Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology Paris, 29 May 2024 - Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the joint Institut Pasteur - Oncovita laboratory is aimed to design and develop vaccine candidates through to proof of concept in humans. Oncovita and the Institut Pasteur have already been working together for several years on the construction and development of new vaccines based on MeasovirR technology, based on the measles vaccine virus. The first candidate under development by Oncovita, MVdeltaC, is an immunotherapeutic treatment for solid tumors and has demonstrated remarkable immunogenic oncolysis properties in human or syngeneic tumor models, e.g. mesothelioma, bladder, neuroblastoma, etc. The production method in accordance with good manufacturing practice (GMP) is under development in order to initiate the first clinical trial. Other candidates have already been constructed and are undergoing preclinical evaluation, against HPV induced cancers or infectious diseases. The joint Institut Pasteur - Oncovita laboratory will also be carrying out research into viral defective interfering RNAs (DI-RNAs) produced by modified recombinant measles viruses. Dr. Anastasia Komarova, director of the joint laboratory, has shown that modified viruses from the measles platform generate large quantities of these DI-RNAs, which could constitute a new generation of innovative therapeutic candidates. Isabelle Buckle, Director of Research Applications and Industrial Relations at the Institut Pasteur, said: “The creation of this joint laboratory is intended to strengthen and perpetuate a collaboration already established with Oncovita, which has borne fruit in terms of innovation. It's a good model for 'de-risking' the science that comes out of a laboratory and bringing solutions to patients. The arrival of Dr Le Bigot, the founder of the Citoxlab group, as Chairman of Oncovita reinforces our ambitious strategy.” According to Dr Jean-François Le Bigot, Chairman of Oncovita: “The joint Institute Pasteur-Oncovita laboratory, which is co-financed and co-directed, gives us access to the greatest potential in France for research in vaccinology, whether therapeutic or prophylactic. They are great hopes for applications in oncology with two products based on oncolytic viruses recently registered in the USA and Japan by pharmaceutical companies." For Pr. Frédéric Tangy, Scientific Director of Oncovita and Co-Director of the joint laboratory who is behind the MeasovirR technology: “this is a new therapeutic class which come to maturity in oncology. Beyond the efficacy of oncolytic viruses themselves, it is important to investigate the potential synergies with other treatments, in particular with check-point inhibitors, as this could increase significantly the efficacy of therapeutic protocols while decreasing their toxicity which is often the critical factor of their usage." About Oncovita : Oncovita is a biotechnology company dedicated to the design and development of new therapeutic and prophylactic vaccines against various types of cancers and contagious diseases. Its vaccine candidates are developed using a proprietary technology platform, MeasovirR, which enables the genome of the measles vaccine virus to be modified. This plug-and-play platform has the capacity to generate candidates with high apoptotic immunogenic activity. Oncovita's mission is to develop its candidates from the preclinical phase through to clinical proof of concept. At the end of 2023, the company was the winner of the ‘Innovations in biotherapies and bioproduction’ call for projects under the France 2030 Health Innovation Plan and received €4.5 million in funding as part of the France 2030 investment plan, operated by Bpifrance. At the same time, Oncovita raised €3.5 million from private investors. These two rounds of financing, totalling €8 million, will enable the company to support the development of its MVdeltaC immunotherapeutic vaccine in oncology. Press contact : Florence Portejoie, FP2COM, fportejoie@fp2com.fr, 06 07 76 82 83 Attachment Oncovita_PR_Joint_Laboratory_Institut_Pasteur_VDEF_2_

Flagship Pioneering eyes $3B fund: The Moderna creator and incubator of more than 100 startups seeks to raise its eighth fund, per a Wednesday SEC filing . The move comes as the Boston firm expands to the UK and Asia-Pacific. Its last fund was a $3.4 billion haul in June 2021. — Kyle LaHucik Phenomic AI announces second pharma deal: The biotech said Thursday that it’s working with Astellas Pharma to figure out whether Phenomic’s antibodies can enhance cell therapies when treating patients with solid tumors. Financial terms of the deal were not disclosed. Earlier this week, Boehringer Ingelheim said it’s paying Phenomic $9 million upfront, plus milestones worth up to $500 million, in a bid to find new targets for certain cancers. — Jaimy Lee